Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
GHK-Cu has more skin research
57 Polkinghorne, K
I actually think this has to do more with the fact that the compounded versions are micro-doses with less side effects
Laboratory research record on Glow | GHK-CU, TB-500, BPC-157 Blend [PMID: 10071911] PubMed laboratory record discussing Glow | GHK-CU, TB-500, BPC-157 Blend in a research context
The latest evidence, however, suggests that as clinical use of GLP-1 drugs expands for both obesity and diabetes, it is imperative that treatment guidelines address not only initiation and titration but also discontinuation and long-term maintenance strategies to sustain therapeutic gains. Clinicians say the findings carry particularly significant implications for younger patients, who may wish or need to stop these medications after achieving desired weight-loss outcomes
